Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 891348, 5 pages
http://dx.doi.org/10.1155/2014/891348
Clinical Study

Efficacy of Zonisamide in Migraineurs with Nonresponse to Topiramate

1Department of Veterinary Internal Medicine and Geriatrics, Kangwon National University, Gangwon-do, Republic of Korea
2Institute of Catholic Integrative Medicine (ICIM), Incheon St. Mary’s Hospital, Catholic University of Korea, Incheon, Republic of Korea
3Department of Neurology, Seoul National University Hospital, 101 Daehakro, Chongno-ku, Seoul 110-744, Republic of Korea

Received 21 March 2014; Revised 28 May 2014; Accepted 17 June 2014; Published 2 July 2014

Academic Editor: Luca Prosperini

Copyright © 2014 Jin-Young Chung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Breslau and B. K. Rasmussen, “The impact of migraine: epidemiology, risk factors, and co-morbidities,” Neurology, vol. 56, no. 6, supplement 1, pp. S4–S12, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. K. Roh, J. S. Kim, and Y. O. Ahn, “Epidemiologic and clinical characteristics of migraine and tension-type headache in Korea,” Headache, vol. 38, no. 5, pp. 356–365, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Pappagallo, “Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine,” Clinical Therapeutics, vol. 25, no. 10, pp. 2506–2538, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. G. Dib, “Focus on topiramate in neuropathic pain,” Current Medical Research and Opinion, vol. 20, no. 12, pp. 1857–1861, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. P. E. Bermejo and R. Dorado, “Topiramate in refractory essential tremor,” Revista de Neurologia, vol. 45, no. 3, pp. 188–189, 2007. View at Google Scholar · View at Scopus
  6. D. Arnone, “Review of the use of topiramate for treatment of psychiatric disorders,” Annals of General Psychiatry, vol. 4, no. 1, article 5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. D. Silberstein, W. Neto, J. Schmitt, and D. Jacobs, “Topiramate in migraine prevention: results of a large controlled trial,” Archives of Neurology, vol. 61, no. 4, pp. 490–495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Brandes, J. R. Saper, M. Diamond et al., “Topiramate for migraine prevention: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 8, pp. 965–973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ängehagen, E. Ben-Menachem, L. Rönnbäck, and E. Hansson, “Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate,” Neurochemical Research, vol. 28, no. 2, pp. 333–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Kececi and S. Atakay, “Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients,” Journal of Clinical Neuroscience, vol. 16, no. 12, pp. 1588–1591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Silberstein, “Topiramate in migraine prevention,” Headache, vol. 45, supplement 1, pp. S57–S65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. T. Lee, K. Chu, J. E. Park, H. J. Park, and M. Kim, “Paresthesia as a favorable predictor of migraine prophylaxis using topiramate,” European Journal of Neurology, vol. 14, no. 6, pp. 654–658, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Frampton and L. J. Scott, “Zonisamide: a review of its use in the management of partial seizures in epilepsy,” CNS Drugs, vol. 19, no. 4, pp. 347–367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. C. L. Schauf, “Zonisamide enhances slow sodium inactivation in Myxicola,” Brain Research, vol. 413, no. 1, pp. 185–188, 1987. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Biton, “Clinical pharmacology and mechanism of action of zonisamide,” Clinical Neuropharmacology, vol. 30, no. 4, pp. 230–240, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Kito, M. Maehara, and K. Watanabe, “Mechanisms of T-type calcium channel blockade by zonisamide,” Seizure, vol. 5, no. 2, pp. 115–119, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. “The International Classification of Headache Disorders: 2nd edition,” Cephalalgia, vol. 24, supplement 1, pp. 9–160, 2004.
  18. Y. L. Lo, S. Y. Lum, S. Fook-Chong, and H. C. Siow, “A pilot study of topiramate dosages for migraine prophylaxis in an Asian population,” Journal of Headache and Pain, vol. 11, no. 2, pp. 175–178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. L. Li, P. Kwan, H. Leung et al., “Topiramate for migraine prophylaxis among Chinese population,” Headache, vol. 47, no. 4, pp. 616–619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Gupta, S. Singh, V. Goyal, G. Shukla, and M. Behari, “Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study),” Headache, vol. 47, no. 3, pp. 402–412, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. P. E. Bermejo and R. Dorado, “Zonisamide for migraine prophylaxis in patients refractory to topiramate,” Clinical Neuropharmacology, vol. 32, no. 2, pp. 103–106, 2009. View at Publisher · View at Google Scholar
  22. V. Villani, A. Ciuffoli, L. Prosperini, and G. Sette, “Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study,” Headache, vol. 51, no. 2, pp. 287–291, 2011. View at Publisher · View at Google Scholar · View at Scopus